SLC5A2 and type 2 diabetes mellitus: Indeed, our results are consistent with the former findings, demonstrating that inhibiting SGLT2 in the T2DM animal model averted the increase in inflammatory mediators and ROS production, eventually preventing diabetes-induced renal injury.